Pal-GHK
- Category
- Skin & Cosmetic
- Administration routes
- Topical
- Regulatory status
- Cosmetic ingredient
What it is
Palmitoyl tripeptide-1 (GHK with a fatty acid tail) is a topical peptide sold for anti-aging skin care, wrinkle reduction, and hydration. The human case is weak: benefits are speculative from small industry-backed trials, and even its better-supported collagen and wound-healing effects (via the parent GHK peptide) are low-confidence. Safety evidence concerns cosmetic use. Cosmetic products are regulated under the FD&C Act without routine FDA premarket approval; no FDA-approved Pal-GHK drug was identified.
Read Full recordStudied uses & evidence
Studied uses(7)
Stimulation of collagen synthesis in dermal fibroblasts
LowShown in cultured fibroblasts specifically for Pal-GHK; not confirmed in living skin or human trials.
Reduction of facial wrinkles (depth, length, and volume)
SpeculativePublished evidence mostly concerns combinations; CIR also summarizes a blinded Pal-GHK-versus-vehicle study involving 15 women.
Improved skin hydration, elasticity, and collagen density
SpeculativeMeasured in a 12-week multi-ingredient trial; effect not isolated to Pal-GHK alone.
Evidence limits
- Evidence Level
- Moderate
Clinical evidence for Pal-GHK is modest but consistent. The peptide's efficacy data comes primarily from manufacturer-sponsored studies (Sederma/Croda for Biopeptide CL and Matrixyl 3000) and small open-label cosmetic trials. These typically involve 15-35 female subjects, durations of 4-12 weeks, and assessment by objective dermatological measurements (corneometry, cutometry, profilometry, ultrasound collagen density). Results consistently show statistically significant improvements in wrinkle parameters, skin elasticity, hydration, and collagen density. However, the active formulations almost always contain Pal-GHK in combination with other actives (Pal-Tetrapeptide-7, growth factors, hyaluronic acid), making it difficult to attribute effects to Pal-GHK alone. In vitro evidence for collagen stimulation by GHK/GHK-Cu is strong and well-replicated across multiple labs since 1988. The CIR Expert Panel's 2018 safety review confirmed the ingredient is safe as used in cosmetics. A 2025 review (PMID 39963574) explicitly noted the 'surprising absence' of rigorous clinical studies isolating Pal-GHK's contribution.
Benefits = confidence in the evidence: High · Medium · Low · Speculative (High requires human randomized trials for that specific benefit)
Cautions & risk summary
General cautions
Pregnancy or breastfeeding
AbsoluteNo human reproductive safety data exists for this peptide. Effects on fetal development are unknown.
Children under 18
AbsoluteNo pediatric safety data. Not recommended for use in minors.
Known hypersensitivity
AbsoluteDiscontinue immediately if allergic reaction occurs (rash, swelling, difficulty breathing).
Risk summary(5)
Risks = level of concern: High · Moderate · Low · Theoretical
Overstated efficacy claims
HighProduct quality variation (research-grade peptide)
ModerateMinimal skin irritation potential
LowLack of reproductive/developmental toxicity data
LowAllergic contact dermatitis (theoretical)
Theoretical
Further reading
- Overview in Full record
- Safety & interactions in Full record
- Research & benefits in Full record
- Regulation & availability in Full record
- Sources in Full record
- Frequently asked questions in Full record
This is educational content compiled from published research, not medical advice. Always consult a licensed healthcare provider before using any peptide. Medical disclaimer
Compiled from published research indexed through March 2026.